High prevalence of medication use in professional football tournaments including the World Cups between 2002 and 2014: a narrative review with a focus on NSAIDs

Philippe M Tscholl,1,2 Martin Vaso,3 Alexis Weber,3 Jiri Dvorak1,3

ABSTRACT
The use of medication in international football has been monitored since the 2002 FIFA World Cup. Team physicians were asked to provide information on prescribed medication 72 h prior to each match for every player. 69% of adult male players reported using medication, with more than half the players using non-steroidal anti-inflammatory drugs (NSAIDs). Up to one-third of all players used NSAIDs prior to every match, regardless of whether they took the field or not. The mean intake of medication was significantly higher during the FIFA Women’s World Cup (0.85 vs 0.77 substances per player and per match, p<0.001), whereas the use of NSAIDs was similar to that for men. In the Under-20 and Under-17 male competitions, the use of medication was lower as 60% of players used some kind of medication and 43% of the players used NSAIDs during the tournaments. Despite the potential side effects of medication, especially of NSAIDs in the recovery process after a sports activity, there is no evidence of decreasing intake. The reported incidence is alarming, and moreover is most probably underestimated, since self-medication by the players or treatment already prescribed by club physicians is not included in the published reports. Future studies should focus on the daily dosage, time of treatment and especially the medical indication for painkilling agents to better understand the underlying factors.

INTRODUCTION
The FIFA Medical Assessment and Research Centre (F-MARC) was the first medical governing body in international sports to systematically document the use of medication; it has done so since the 1998 FIFA World Cup. For FIFA tournaments, data are collected in connection with doping control after each match. Team physicians are asked to provide information about “any medication taken by the players or administered to them in the 72 hours preceding the match ...” The team doctor shall also note down, on the basis of the information at his disposal, medications and food supplements taken by the players without medical prescription”.1

Other sports governing bodies such as the IOC and the International Association of Athletics Federations (IAAF) followed suit but only for athletes selected for doping control.8-9

For this review, we present published data from 10 men’s, women’s and male adolescent FIFA World Cups8-8 (see table 1) and compare them with reports from other sports. This review, and the discussion of overmedication, should be viewed in the context of international campaigns warning against the harms of excessive medication.9

The 2002, 2006, 2010 and 2014 FIFA World Cups
The mean intake of medication in male professional football is consistent for all World Cups with 0.77 substances per player and per match (see table 1). The most frequently prescribed substance group was non-steroidal anti-inflammatory drugs (NSAIDs; see figure 1), representing 36% of all substances. β-2-Agonists were reported in 44 players (1.2% of all substances; see table 2) during the four tournaments. However, since β-2-agonists are usually taken during the entire season and do not require a therapeutic use exemption anymore, a national team physician might ignore its use in some players. The use of medication over time did not change significantly, neither in the amount nor in its distribution of substance groups.

FIFA Women’s World Cup and the Under-17 and Under-18 FIFA World Championships
The reported use of medication during the 2003 and 2007 FIFA Women’s World Cup was significantly higher than in the Men’s World Cups (0.85 vs 0.77, p≤0.001) and than in adolescent football players participating in Under-17 (U-17) and U-20 tournaments (0.51, p≤0.001; see table 1). Contraceptive agents were not included in the analysis. Whereas the incidence of the use of NSAIDs was similar between adult male and female players, significantly fewer NSAIDs were administered to adolescent players, suggesting increased consumption with age (see table 2).

In 14.9% of female players, oral contraceptive use was reported. This is less than what was reported by Alaranta et al.10 for other team sport events (24%), and especially in speed, power and endurance events (40%).

NSAIDs and other analgesics
The NSAIDs category was the one that was most reported in every tournament (see figure 1). In total 54.5% of male players and 50.9% of female players participating in the FIFA World Cup used an NSAID at least once during the tournament; 43.3% adolescent players did so too. Hence, on average, more than seven male and female players per national team were using NSAIDs prior to every match, as were 4.5 players in U-17 and U-20 tournaments (see table 2). Ten per cent of the male...
and female players were using more than one type of NSAIDs at one time, thus increasing the risk of side effects. There was no difference in use of medication and NSAIDs, in particular between players participating in the match and substitutes who did not play at all; nor was there a correlation between injuries reported and reported use of medication. The most frequently prescribed application form was the oral route (93%). In only 7%, NSAIDs were administered topically, although percutaneous application of NSAIDs might be as efficient as oral preparation in the treatment of soft-tissue injuries. Other analgesics (such as paracetamol (acetaminophen) and metamizol) were rarely used (5.4% of all substances), although they might be as efficient as oral preparation in the treatment of soft-tissue injuries.

Injections with local anaesthetics or corticosteroids were mostly intra-articular, followed by intramuscular applications. They were performed in almost 8% of all players participating in adult male tournaments, and in about 3% of female adults and male adolescent football players (see table 2). The amount of administration seems to depend highly on the national team physician. Whereas 23 of 32 team physicians did not perform any injections for musculoskeletal symptoms during the 2014 World Cup, four players from one national team received peritendinous or intra-articular glucocorticoid injections prior to almost every match. The indication for these injections was not reported. Nevertheless, such repetitive practice during a tournament prior to each match is questionable since the long-term safety of intra-articular application may substantially worsen the injury if play is resumed immediately.

The high use of medication and NSAIDs in particular is not limited to international football. Similar use of medication has been reported during the Sydney Olympics in 2000, in top-level track and field athletes, triathletes and also in collegiate athletes. An unpublished review of articles published between 2003 and 2010 found that power/sprint disciplines show a similar ‘substance profile’ as ball sports. Although endurance athletes rarely used NSAIDs (6.8±0.2 vs 27.3±0.4 in power/sprint disciplines), their declared use of corticosteroids (15.0±0.3 vs 4.6±0.1) and β-2-agonists (6.8±0.2 vs 2.3±0.1) increased significantly (p<0.05). In popular events such as the Bonn Marathon 2009, Berlin Marathon 2010 and El Andalus Ultramarathon, 47–61% of athletes used NSAIDs or other painkilling agents. The participants using NSAIDs had an almost five times higher incidence of adverse events (gastrointestinal cramps and bleeds, Table 1: Tournament information

<table>
<thead>
<tr>
<th>Tournament</th>
<th>Teams (n)</th>
<th>Players (n)</th>
<th>Matches (n)</th>
<th>Reports (n)</th>
<th>Medications prescribed (n)</th>
<th>Intake of medication (per player, per match)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WC 2014</td>
<td>32</td>
<td>736</td>
<td>64</td>
<td>2944</td>
<td>2346</td>
<td>0.80</td>
</tr>
<tr>
<td>WC 2010</td>
<td>32</td>
<td>736</td>
<td>64</td>
<td>2944</td>
<td>2335</td>
<td>0.79</td>
</tr>
<tr>
<td>WC 2006</td>
<td>32</td>
<td>736</td>
<td>64</td>
<td>2944</td>
<td>2052</td>
<td>0.70</td>
</tr>
<tr>
<td>WC 2002</td>
<td>32</td>
<td>736</td>
<td>64</td>
<td>2944</td>
<td>2392</td>
<td>0.81</td>
</tr>
<tr>
<td>W-WC 2007</td>
<td>16</td>
<td>336</td>
<td>32</td>
<td>1344</td>
<td>1200</td>
<td>0.89</td>
</tr>
<tr>
<td>W-WC 2003</td>
<td>16</td>
<td>320</td>
<td>32</td>
<td>1280</td>
<td>1036</td>
<td>0.81</td>
</tr>
<tr>
<td>U-20 2007</td>
<td>24</td>
<td>504</td>
<td>52</td>
<td>2184</td>
<td>965</td>
<td>0.44</td>
</tr>
<tr>
<td>U-20 2005</td>
<td>24</td>
<td>504</td>
<td>52</td>
<td>2184</td>
<td>1248</td>
<td>0.57</td>
</tr>
<tr>
<td>U-17 2007</td>
<td>24</td>
<td>504</td>
<td>52</td>
<td>2184</td>
<td>1036</td>
<td>0.47</td>
</tr>
<tr>
<td>U-17 2005</td>
<td>16</td>
<td>320</td>
<td>32</td>
<td>1280</td>
<td>717</td>
<td>0.56</td>
</tr>
<tr>
<td>Total</td>
<td>248</td>
<td>5432</td>
<td>508</td>
<td>22 232</td>
<td>15 327</td>
<td>0.71</td>
</tr>
</tbody>
</table>

U, under; W-WC, Women’s World Cup.
haematuria or cardiovascular events, such as arrhythmia and palpitation), which increased significantly with the analgesic dosage. It is noteworthy that serious adverse events occurred only in patients who were using NSAIDs (3 athletes with oliguria/anuria using ibuprofen, and 4 gastric bleeds, all using 500–1000 mg acetylsalicylic acid).23 It is alarming that most athletes are not aware of the potentially deleterious adverse effects of NSAIDs after strenuous exercise, and that physicians are rarely asked for advice prior to its use.16–20,23

The routine use of NSAIDs in sport is harmful in the short term and potentially also in the long term. Owing to its anti-inflammatory effect, NSAIDs delay bone healing,24,25 decrease protein synthesis and inhibit peritendinous hyperaemia and satellite cells in skeletal muscle after exercise.26,27 A randomised controlled trial has shown that NSAIDs permit earlier mobilisation, weight bearing and return to play compared with placebo after ankle sprains. However, there are also reports of more swelling, an increased incidence of residual instability and a decreased range of motion in ankles.29 This might be due to lower load-to-failure properties of the ‘healed’ ligament after the use of NSAIDs.30 Also, DOMS (delayed onset of muscle soreness) can be treated with NSAIDs to reduce pain and enable earlier return to play. However, accompanying muscle weakness and imbalance are not improved. A precipitate return to sport before muscular balance is re-established might put the player at risk for inappropriate biomechanical stress and overuse injuries.31,32

Knowledge translation and important questions
F-MARC campaigned to reduce the use of NSAIDs prior to the 2010 FIFA World Cup by informing all team physicians about NSAIDs and their potential side effects on recovery processes after exercise bouts and on tissue healing. Despite this initiative, the reported intake of NSAIDs remained unchanged in 2010 and 2014.

Our review poses several salient questions: What is the indication for which one-third of players use NSAIDs prior to every match, particularly when this greatly exceeds the rate of reported injuries during the FIFA World Cup? Is the high prescription practice due to a high number of non-time loss, chronic and overuse injuries?33 Are painkilling medications used routinely by the players to overcome fatigue and muscle soreness due to physical overload, or even improve recovery? Or has it simply become ‘part of the game’ for players and team physicians?

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

Table 2 Number of players using a substance prior to a match or during the tournament

<table>
<thead>
<tr>
<th></th>
<th>2002–2014 FIFA WC Players (n)</th>
<th>2003–2007 FIFA Women’s WC Players (n)</th>
<th>2005–2007 FIFA U-17/1-20 WC Players (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Per match</td>
<td>During the tournament</td>
<td>Per match</td>
</tr>
<tr>
<td>Any medication</td>
<td>5179</td>
<td>44.0</td>
<td>2029</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>3737</td>
<td>31.7</td>
<td>1604</td>
</tr>
<tr>
<td>Injections*</td>
<td>422</td>
<td>3.6</td>
<td>234</td>
</tr>
<tr>
<td>Analgesics</td>
<td>588</td>
<td>5.0</td>
<td>376</td>
</tr>
<tr>
<td>β-2-Agonists</td>
<td>142</td>
<td>1.2</td>
<td>44</td>
</tr>
<tr>
<td>Myorelaxants</td>
<td>395</td>
<td>3.4</td>
<td>225</td>
</tr>
<tr>
<td>All medication</td>
<td>2985</td>
<td>25.3</td>
<td>984</td>
</tr>
</tbody>
</table>

*Injections of corticosteroids and/or anaesthetics.
NSAID, non-steroidal anti-inflammatory drugs; U, under; WC, World Cup.
High prevalence of medication use in professional football tournaments including the World Cups between 2002 and 2014: a narrative review with a focus on NSAIDs

Philippe M Tscholl, Martin Vaso, Alexis Weber and Jiri Dvorak

doi: 10.1136/bjsports-2015-094784

Updated information and services can be found at:
http://bjsm.bmj.com/content/49/9/580

References

This article cites 31 articles, 9 of which you can access for free at:
http://bjsm.bmj.com/content/49/9/580#BIBL

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Open access (272)
Drugs: musculoskeletal and joint diseases (87)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/